ウステキヌマブ治療を受けたクローン病の小児患者の再発性肺胸炎:症例報告
Marta Freixas Bermejo1, Luis Riera Soler2, Laura García Martínez3
1Pediatric Gastroenterology Department, Hospital Vall de Hebrón, Barcelona, Spain.
Case reports in gastroenterology
|August 29, 2025
まとめ
クローン病の患者では,ウステキヌマブ治療を開始した後に肺胸炎が再発した. この有害事象は,薬剤の中止時に解消され,再挑戦時に再発し,潜在的な安全性に関する懸念を強調した.
科学分野:
- 胃腸内科
- 肺科
- 免疫学
背景:
- クローン病は慢性的な炎症性腸疾患です.
- ウステキヌマブは,中等から重度のクローン病に使用される,IL-12/23を標的とした免疫抑制生物学的療法です.
- 肺胸炎は,特定の生物学的治療に伴う 希少だが深刻な合併症です.
関連する概念動画
Pneumothorax-II
352
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
352
Pneumothorax-I
340
A pneumothorax is a condition where air builds up in the space between the lung and the chest wall, causing the lung to collapse. This condition arises when air enters the space between the parietal and visceral pleura, disrupting the negative pressure essential for lung inflation. This can lead to a partial or complete collapse of the lung.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
340
Pulmonary Cycle: Exhalation
1.8K
In terms of human respiration, the act of expelling air, known as exhalation (or expiration), operates on the principle of pressure gradients. During expiration, the pressure within the lungs exceeds that of the surrounding atmosphere. Under normal conditions, quiet breathing involves passive exhalation and is free of muscular contractions. This is because the exhalation process is driven by the natural elastic recoil of the lungs and chest wall, both of which have an inherent tendency to...
1.8K
Cystic Fibrosis: Management
222
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
222
Chronic Obstructive Pulmonary Disease-V: Management
2.7K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.7K
COPD: Management Using Bronchodilators and Corticosteroids
305
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
305


